Skip to main content

Table 3 Cox regression analysis for factors possibly influencing OS and DFS in patients with cervical cancer

From: The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer

Factors

Recurrence-free survival

Overall survival

Univariate

Multivariate

Univariate

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age (≥50 vs <50)

0.138 (0.029–0.648)

0.012

0.104 (0.02–0.567)

0.01

0.111 (0.023–0.527)

0.005

0.6 (0.397–0.906)

0.015

Tumor size (≥4 vs <4 cm)

1.117 (1.03–1.452)

0.002

0.156 (0.029–1.217)

0.079

1.95 (1.024-1.375)

0.001

0.336 (0.186–1.609)

0.082

Histology (well and moderate vs poor)

0.346 (0.1–1.196)

0.094

0.365 (0.086–1.543)

0.173

1.042 (0.682–1.590)

0.196

0.447 (0.128–1.563)

0.207

LN metastasis (absent vs present)

5.378 (1.556–18.58)

0.008

0.467 (0.078–2.774)

0.404

5.111 (1.479–17.659)

0.01

0.592 (0.311–1.126)

0.455

Vascular space involvement (absent vs present)

12.262 (1.553–96.82)

0.017

1.612 (0.057–38.489)

0.805

11.737 (1.487–92.552)

0.019

0.777 (0.401–1.505)

0.565

Lymphatic invasion (absent vs present)

10.125 (1.213–85.32)

0.021

7.531 (0.325–156.960)

0.239

11.894 (1.507–93.909)

0.017

1.202 (0.642–2.252)

0.746

Deep stromal invasion (absent vs present)

8.498 (1.076–67.086)

0.042

2.498 (0.323–26.631)

0.45

8.97 (1.135–70.892)

0.038

5.733 (0.593–55.392)

0.702

Podoplanin (positive vs negative)

10.759 (1.363–84.944)

0.024

0.853 (0.023–31.877)

0.932

11.363 (1.438–69.791)

0.021

3.238 (0.349–30.078)

0.878

Vimentin (positive vs negative)

11.959 (2.535–56.407)

0.002

11.213 (1.67–41.774)

0.003

12.515 (2.649–59.121)

0.001

8.386 (1.475–47.66)

0.012

TP53 (positive vs negative)

6.443 (1.815–22.873)

0.004

3.467 (0.929–12.946)

0.654

7.768 (2.161–27.918)

0.006

2.284 (0.521–10.014)

0.27

  1. Hazard ratios with 95% confidence intervals (95% CI) were estimated and adjusted by indicated clinical parameters